Media Coverage

Atomwise, Charles River Labs Partner to Provide AI Services in Drug Discovery

drug discovery

MedCity News

A firm that uses artificial intelligence in drug development is partnering up with one of the country’s largest contract research organizations to offer the technology to drugmakers.

San Francisco-based Atomwise said Friday it had formed the partnership with Wilmington, Massachusetts-based Charles River Laboratories, adding the deal is potentially worth up to $2.4 billion for the technology company in royalties.

Under the agreement, Atomwise will receive technology access fees, milestone payments and royalties from clients while supporting hit discovery, hit-to-lead and lead optimization. The firm said that it and the CRO working together would provide biotechnology and pharmaceutical companies with greater opportunity to identify chemically diverse hit compounds.

Read the Full Story